References
- Dzau, V. J., Mann, M., Morishita, R. and Kaneda, Y., 1996, Fusigenic viral liposome for gene therapy in cardiovascular diseases. Proceedings of National Academy of Sciences (USA), 93, 11421–11425.
- Hirano, T., Fujimoto, J., Ueki, T., Yamamoto, H., Iwasaki, T., Morishita, R., Sawa, Y., Kaneda, Y., Takahashi, H. and Okada, E., 1998, Persistent gene expression in rat liver in vivo by repetitive transfections using HVJ-liposome. Gene Therapy, 5, 459–464.
- Kaneda, Y., 1994, Virus (Sendai virus envelopes) mediated gene transfer. In Cell Biology: A Laboratory Handbook, J. E. Celis, ed. (Academic Press: Orlando, Florida) vol 3, pp. 50–57.
- Kaneda, Y., Iwai, K. and Uchida, T., 1989a, Increased expression of DNA cointroduced with nuclear protein in adult rat liver. Science (Washington D.C.) 243, 375–378.
- Kaneda, Y., Iwai, K. and Uchida, T., 1989b, Introduction and expression of the human Insulin gene in adult rat liver. Journal of Biological Chemistry 264, 12126–12129.
- Morishita, R., Gibbons, G. H., Ellison, K. E., Nakajima, M., Zhang, L., Kaneda, Y., Ogihara, T. and Dzau, V. J., 1993, Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia. Proceedings of National Academy of Sciences (USA), 90, 8474–8478.
- Morishita, R., Gibbons, G. H., Horiuchi, M., Ellison, K. E., Nakajima, M., Zhang, L., Kaneda, Y., Ogihara, T and Dzau, V. J., 1995, A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. Proceedings of National Academy of Sciences (USA), 92, 5855–5859.
- Saeki, Y., Matsumoto, N., Nakano, Y., Mori, M., Awai, K. and Kaneda, Y., 1997, Development and characterization of cationic liposomes conjugated with HVJ (Sendai virus); Reciprocal effect of cationic lipid for in vitro and in vivo gene transfer. Human Gene Therapy, 8, 1965–1972.
- Saeki, Y., Wataya-Kaneda, M., Tanaka, K. and Kaneda, Y., 1998, Sustained transgene expression in vitro and in vivo using an Epstein-Barr virus replicon vector system combined with HVJ- liposomes. Gene Therapy, 5, 1031–1037.
- von der Leyen, H. E., Gibbons, G. H., Morishita, R., Lewis, N. P., Zhang, L., Nakajima, M., Kaneda, Y., Cooke, J. P. and Dzau, V. J., 1995, Gene therapy inhibiting neointimal vascular lesion; in vivo transfer of endothelial cell nitric oxide synthase gene. Proceedings of National Academy of Sciences (USA), 92, 1137–1141.